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Abstract
The potential use of natural cyclodextrins and their synthetic derivatives have been studied extensively in pharmaceutical
research and development to modify certain properties of hydrophobic drugs. The ability of these host molecules of
including guest molecules within their cavities improves notably the physicochemical properties of poorly soluble drugs,
such as albendazole, the first chosen drug to treat gastrointestinal helminthic infections. Thus, the aim of this work was to
synthesize a beta cyclodextrin citrate derivative, to analyze its ability to form complexes with albendazole and to evaluate its
solubility and dissolution rate. The synthesis progress of the cyclodextrin derivative was followed by electrospray mass
spectrometry and the acid-base titration of the product. The derivative exhibited an important drug affinity. Nuclear
magnetic resonance experiments demonstrated that the tail and the aromatic ring of the drug were inside the cavity of the
cyclodextrin derivative. The inclusion complex was prepared by spray drying and full characterized. The drug dissolution
rate displayed exceptional results, achieving 100% drug release after 20 minutes. The studies indicated that the inclusion
complex with the cyclodextrin derivative improved remarkably the physicochemical properties of albendazole, being a
suitable excipient to design oral dosage forms.
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Introduction
Cyclodextrins (CDs) are cyclic oligosaccharides consisting of six,
seven or eight linked D-glucopyranose units (a, b and c -CDs,
respectively). Due to the chair conformation of the glucopyranose
units, CDs molecules have torus macro-ring shape, like a
truncated cone, with a hydrophobic cavity and a hydrophilic
surface [1]. CDs are well known to form inclusion complexes with
a variety of drugs resulting in the improvement of aqueous
solubility [2]. Therefore, CDs have been extensively studied to
improve certain properties of the drugs, such as aqueous solubility
of hydrophobic drugs avoiding the use of organic solvents,
surfactants, or lipids, to increase dissolution rates and oral
bioavailability [3]. Additionally, CDs can also reduce gastrointes-
tinal and ocular irritation, eliminate unpleasant odors or taste, and
prevent drug-additive interactions [4,5,6,7].
The enhancement of drug activity or the reduction of side
effects can be achieved by inclusion complex formation through a
molecular encapsulation process. The CD complexation enables
the development of formulations for drugs that are difficult to
formulate and deliver with the existing pharmaceutical excipients.
To extend the functions of pharmaceutical additives, the
combination of molecular encapsulation with other carrier
materials is also an effective and a valuable tool in the
improvement of drug properties.
Numerous chemical modifications of the CDs have been
synthesized and novel derivatives are constantly being developed.
Since each CD hydroxyl group differs in its chemical reactivity,
the random substitution produces an important increase in
solubility due to the decrease in the crystalline state and may
also be helpful to overcome the formation of kidney damaging
crystalline cholesterol complexes and also to achieve efficient drug
delivery systems [8].
Albendazole (ABZ), methyl [5-(propyl-thio)-1-H-benzimidazole-
2yl] carbamate, is a benzimidazole derivative with a broad
anthelmintic spectrum [9]. ABZ is useful against several gastro-
intestinal parasites such as those producing hydatidosis. ABZ,
belongs to the class II in the Biopharmaceutics Classification
Systems (BCS). It is a poorly water soluble (1 mg/mL) and highly
lipophilic drug (log P of 2.55), presenting low or erratic
bioavailability leading to a variable oral absorption (#5%) [10].
After oral administration, a drug must dissolve in the gastric
fluids, in order to be absorbed into the systemic circulation. This
process determines the rate and degree of absorption [11]. Several
works have been carried out to improve the aqueous solubility and
dissolution rate of ABZ. In this context it is worth mentioning, the
preparation of solid dispersions [12], micellar drug delivery
systems [13], microencapsulation [14], nanosuspensions [15],
nanosize liposomes [16], ternary systems with polymers and CD
[17] and inclusion complexes with CDs [18].
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Particularly, when CDs were used to form inclusion complexes,
different methods have been employed to characterize the
interactions between guest molecules and CD, such as nuclear
magnetic resonance (NMR) conductometric titration, potentio-
metric, spectrophotometric and fluorometric techniques, among
others [19,20,21,22].
However, in some instances, there are uncertainties regarding
the complex stoichiometries and the lack of structural information
using these techniques [23]. Electrospray ionization mass spec-
trometry (ESI-MS) is a powerful means of studying reaction
products and non-covalent complexes between ‘‘host-guest’’ with
high sensitivity and rapidity, at a very low level of sample
consumption [24,25,26].
The characterization of the CD derivative and the inclusion
complex is extremely important to understand the host-guest
molecule interaction. Different techniques, such as ESI-MS and
NMR spectroscopy (1H-13C Heteronuclear Single Quantum
Correlation, HSQC, Heteronuclear Multiple Bond Correlation,
HMBC and Rotating-Frame Overhauser Effect Spectroscopy,
ROESY) were used to thoroughly investigate the synthesis
reaction and to study the structural characteristics of supramolec-
ular aggregates, which exhibited distinct properties from both
‘‘guest’’ and ‘‘host’’ molecules. The stoichiometry and equilibrium
constants for complex formation, which allowed a quantitative
description of the solubility behavior, were determined by phase-
solubility studies.
Thus, the aim of this work was to improve a simple
methodology to synthesize a b-CD citrate derivative (C-b-CD),
to analyze their ability to form complexes with ABZ and to
evaluate the solubility and dissolution rate of ABZ, the first chosen
drug to treat gastrointestinal helminthic infections, one of the
major health problems in many developing countries.
Materials and Methods
Materials
ABZ, b-CD, hydroxypropyl b-CD, methyl b-CD were supplied
by Sigma-Aldrich Chemie GmbH (Steinheim, Germany).
All other chemicals were of analytical grade.
Methods
Synthesis of b-CD citrate derivative. The C-b-CD was
synthesized based on the reports written by S. Chaleawlert-umpon
et al. with minor modifications [27]. Citric acid (CA)
(10.57 mmol, 2.03 g) was dissolved in water (1.2 mL), and
followed by the addition of b-CD (1.76 mmol, 2.00 g). The molar
ratio of b-CD and CA was 1:6. The reaction mixture was refluxed
at 100uC for 6 h and samples were taken off at 1, 2, 3, 4, 5 and 6 h
to follow the progress of the reaction. Then the product (C-b-CD)
was precipitated employing isopropanol and centrifuged at
6000 rpm. The precipitate was washed with isopropanol to
remove un-reacted CA. The procedure was repeated until the
pH of supernatant was neutral. The nonappearance of free CA
was also confirmed by ESI-MS. Finally, the product was dried
24 h at 60uC.
The reaction progress was followed by two methods: ESI-MS
analysis and measuring the total carboxyl groups by titration
[27,28].
Figure 1. Reaction progress. Total amount of carboxyl groups vs
time.
doi:10.1371/journal.pone.0088234.g001
Figure 2. Phase solubility diagram. Concentration of ABZ against increasing concentrations of CDs.
doi:10.1371/journal.pone.0088234.g002
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a) ESI-MS analysis. High Resolution Mass spectra were
recorded on a Bruker micrOTOF-Q II spectrometer (Bruker-
Daltonics, Bremen, Germany). MS and MS-MS were carried
out as followed: source type: ESI, ion polarity: positive and
negative, scan begin: 200 m/z, scan end: 2000 m/z, set
nebulizer: 0.4 bar, set dry heater: 180 uC, set dry gas: 4.0 L/
min, set capillary: 4500 V, set end plate offset: -500 V, set
collision Cell RF: 1000–1500 Vpp. Collision energy for MS
experiments: 35 eV.
Specifically for low molecular weight acidic molecules such as
CA, it has been used the negative ion, tune low mode, under the
following conditions, set collision Cell RF: 150.0 Vpp [29].
All the samples were dissolved in formic acid (0.4% v/v) and
then diluted with water and methanol.
b) Total carboxyl content of C-b-CD. The total amount of
carboxyl groups exhibited in the final product was deter-
mined by acid-base titration, based on previous
Carboxyl content~
Va{Vbð Þ xN x 100
W
works [22,30]. An accu-
rate amount of C-b-CD was added to a conical flask
containing an excess of 0.1 M NaOH solution and stirred
for 1 h. The C-b-CD was completely dissolved, then, the
NaOH was titrated with 0.1 N HCl solution employing
phenolphthalein as an indicator [30]. The total amount of
carboxyl groups of C-b-CD was calculated as follows:
Carboxyl content~
Va{Vbð ÞxN x 100
W
where N is the normality of HCl (eq/L), Vb is the volume of
HCl without sample (mL), Va is the volume of HCl in presence of
sample (mL), and W is the weight of sample (g).
Solubility diagrams. Solubility diagrams were obtained
according to Higuchi and Connors [31]. Briefly, excess amounts
of ABZ (30 mg) was added to 10 mL of distilled water (pH 6.3)
containing various concentrations (0.60 mM) of b-CD, hydro-
xypropyl b-CD (HP-b-CD), methyl b-CD (M-b-CD) and the
synthesized C-b-CD. Samples were shaken for 72 h in an elliptical
shaker at 180 rpm and 37uC and then filtered through a 0.45 mm
membrane filter (Advantec MFS, Inc.). ABZ concentration in the
filtrate was spectrophotometrically analyzed at 291 nm (Boeco S-
26 spectrometer, Hamburg, Germany). The phase-solubility
diagram was therefore obtained and the complex formation
constant (Kf) was calculated [32,33] according to the equation: S
(slope), S0 (solubility of the drug in the absence of CD)
Kf~S=So(1{S)
Figure 3. FT-IR spectra. A: ABZ (pure drug), B: C-b-CD, C: ABZ:C-b-CD
obtained by PM, D: ABZ:C-b-CD obtained by SD.
doi:10.1371/journal.pone.0088234.g003
Figure 4. DSC thermograms. A: ABZ (pure drug), B: C-b-CD, C:
ABZ:C-b-CD obtained by PM, D: ABZ:C-b-CD obtained by SD.
doi:10.1371/journal.pone.0088234.g004
Figure 5. X-ray diffraction patterns. A: ABZ (pure drug), B: C-b-CD,
C: ABZ:C-b-CD obtained by PM, D: ABZ:C-b-CD obtained by SD.
doi:10.1371/journal.pone.0088234.g005
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Each experiment was performed in triplicate.
Preparation of the inclusion complexes and physical
mixtures. The inclusion complexes were prepared by spray
drying (SD) method dissolving ABZ (0.56 mol) in acetic acid
(10 mL). Then, C-b-CD (0.56 mol) and water (20 mL) were added
to the solution. The resulting solution was spray-dried in a Mini
Spray Dryer Buchi B-290 (Flawil, Switzerland) under the following
conditions: inlet temperature: 130uC, outlet temperature: 70uC,
air flow: 38 m3/h, feed: 5 mL/min, and aspirator set: 100%.
Additionally, physical mixtures (PM) between C-b-CD and ABZ
were prepared in a mortar by mixing the drug and carrier for 10
minutes.
C-b-CD and Complex Characterization
Fourier transform infrared spectroscopy. Fourier trans-
form infrared (FT-IR) spectra were obtained by an FT-IR-
Prestige-21. Shimadzu (Tokyo, Japan) using the KBr disk method
(2 mg sample in 100 mg KBr). Scanning range was 450 to
3,900 cm21 with a resolution of 1 cm21.
Differential Scanning Calorimetry. Differential scanning
calorimetry (DSC) was performed on a Shimadzu TA-60 (Kyoto,
Japan) calorimeter, using 5 mg samples in crimped aluminium
pans. The instrument was calibrated using indium and zinc as
standards. Nitrogen was used as a purge gas and an empty
aluminium pan was used as a reference. Each sample was scanned
at a rate of 5uC/min from 25 to 350uC, under N2 atmosphere
(flow rate 30 mL/min).
X-Ray Diffraction. Data collection was carried out in
transmission mode on an automated X’Pert Phillips MPD
difractometer (Eindhoven, The Netherlands).
X-ray diffraction (XRD) patterns were recorded using CuKa
radiation (l= 1.540562 A˚), a voltage of 40 kV, 20 mA current
and steps of 0.02u on the interval 2h= 10u–40u. Low peak
broadening and background were assured by using parallel beam
geometry by means of an X-ray lens and a graphite mono-
cromator placed before the detector window.
Data acquisition and evaluation were performed with the Stoe
Visual-Xpow package, Version 2.75 (Germany).
ESI-MS Analysis. The stoichiometry of the complex was
confirmed by mass spectrometry with high resolution; the
equipment used was a micrOTOF-Q II spectrometer, Bruker-
Daltonics (Bremen,
Germany). To perform this analysis 1 mg of ABZ and an excess of
C-b-CD were dissolved in 1 mL of formic acid (0.4% v/v), and
then diluted 1/100 with methanol: water (50:50). These studies
were performed under the same conditions followed in ESI-MS
analysis. For the MS-MS analysis, 30 eV energy of fragmentation
was used.
NMR Spectroscopy. A complete NMR study (HSQC,
HMBC and CIGAR-HMBC spectra) was conducted to determine
the b-CD position modification.
ROESY Experiments. Two-dimensional rotating-frame
Overhauser effect epectroscopy (ROESY) experiments were used
to confirm the current complexation of ABZ with the C-b-CD, as
well as to characterize their binding mode. ABZ:C-b-CD complex
(10 mg) was solubilized in 0.5 mL 0.1 N DCl in D2O, and filtrated
(0.45 mm Millipore membrane filter).
ROESY measurements were performed with a Bruker Avance
300 instrument (Karlsruhe, Germany) with a 5 mm probe using
the roesyph pulse sequence (Bruker) with the experimental
conditions as follows: 32 scans, acquisition time 0.222 s, pulse
delay 1.92 s and 512 data points [34]. The resonance at 4.7 ppm
was used as internal reference due to residual solvent water (H2O
and HDO).
Dissolution Studies. Dissolution studies were performed in
900 mL HCl 0.1 N at 37uC, according to U.S. Pharmacopeia
(USP) Apparatus 2 (SR8 8-Flask Bath, Hanson Research, Chats-
worth, CA) with paddle rotating at 50 rpm [35]. Samples of ABZ
pure drug, PMs and SDs equivalent to 100 mg of the drug were
spread on the surface of the dissolution medium and the time 0
was recorded. At appropriate time intervals, 5 mL of samples were
withdrawn, and filtered (pore size 0.45 mm). The amount of drug
released was determined by UV analysis by measuring the
absorbance spectrophotometrically at 291 nm.
Results and Discussion
Reaction Progress
To evaluate the progress of the synthesis of the CD derivative,
the total carboxyl content of C-b-CD at different reaction times
was analyzed by acid-base titration (Figure 1). A maximum of
carboxyl groups content was reached after a 4 h reaction.
Additionally, to corroborate the b-CD derivative reaction
progress, samples were assayed by means of ESI-MS analysis.
The analysis in negative ionization mode allowed observing a
molecular ion with m/z 1307.3. The signal of b-CD derivative
appears at 1307.3 and the b-CD starting material at m/z 1133.3.
These results confirmed the degree of substitution of C-b-CD by
the calculation of the molecular weight.
Meanwhile 4 h of reaction progress, the intensity of the signal of
the b-CD starting material continuously decreased while the signal
of the product was increased. After 4 h of the running chemical
Figure 6. MS-MS spectrum. Product ion mass spectrum of the protonated molecules ABZ:C-b-CD.
doi:10.1371/journal.pone.0088234.g006
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reaction no changes in the spectrum were observed. This result
was consistent with that obtained by carboxylic titration.
Furthermore, it was also verified by ESI-MS analysis the
nonappearance of un-reacted CA. These spectra were done under
negative ion, tune low mode conditions to stabilize low molecular
weight ions.
Figure 7. ROESY spectrum. A: ABZ proton labelling, B: C-b-CD proton labelling. C and D: Plot of two dimensional ROESY spectrum of ABZ in the
presence of C-b-CD.
doi:10.1371/journal.pone.0088234.g007
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Solubility Diagrams ABZ:CDs
The phase solubility diagrams of ABZ:b-CD, ABZ:HP-b-CD,
ABZ:M-b-CD, ABZ:C-b-CD are represented in Figure 2.
The corresponding complex formation constants (Kf) showed
the relationship between ABZ and the CDs, fitting an AL-type
system very well [31]. This type of curves indicated the formation
of soluble 1:1 type inclusion complex. The Kf value obtained for
the inclusion complex between ABZ and C-b-CD was
1037.34 M21, suggesting a relatively stable complex in compar-
ison with the Kf obtained with traditional CDs (b-CD: 67.90 M21;
HP-b-CD: 313.16 M21; and M-b-CD: 336.70 M21). It could then
be suggested that the stability of the complex ABZ:C-b-CD could
be due to an interaction between the acidic groups of the
derivative and the basic groups of ABZ.
C-b-CD and Complex Characterization
FT-IR. The FT-IR spectra of ABZ, C-b-CD and systems
ABZ:C-b-CD obtained by PM and SD techniques are represented
in Figure 3. The C-b-CD showed a peak at 1732 cm21
corresponding to an ester group (which was formed by the
reaction between carboxyl groups of the CA and hydroxyls groups
of the b-CD). The spectrum of ABZ:C-b-CD (PM) clearly
exhibited the peaks corresponding to the samples of ABZ and
C-b-CD and no shifting could were observed. On the other hand
some peaks could be detected in spectrum D in accordance with
ABZ patterns (1632 cm21 corresponding to the carbonyl group).
This fact could indicate the decrease in the crystallinity of the solid
structure of ABZ loaded in the inclusion complex prepared by SD.
Differential Scanning Calorimetry. DSC thermograms of
ABZ, C-b-CD and ABZ:C-b-CD prepared by PM and SD are
shown in Figure 4. The characteristic sharp melting peak of ABZ is
observed at 196.84 uC. The intensity of the drug endothermic
peak was also exhibited in the system obtained by PM. In this
particular case, the smaller intensity of the ABZ peak could be due
to the dilution effect produced by the carrier ratio. The peak was
also present in the system obtained by SD but showed less
intensity. This decrease in the ABZ peak could be due to the
structure of the C-b-CD and the SD process [36].
X-Ray Diffraction. Figure 5 shows the XRD spectra of ABZ,
C-b-CD and the systems ABZ:C-b-CD obtained by PM and SD.
The derivative C-b-CD showed an amorphous structure; ABZ
presented intense and characteristic peaks at 2h 11.51; 17.85;
22.09 y 24.54. The diffraction patterns of ABZ in the PM were
similar to the pure drug, indicating that the crystallinity of ABZ
did not essentially change. The smaller intensity of some peaks of
ABZ could be due to the dilution effect in the presence of the C-b-
CD. On the other hand, diffraction patterns of SD systems showed
fewer, broader, and less intense peaks, showing only two weak
peaks of the drug at 2h 17.85 and 24.54 which suggests that ABZ is
in an amorphous state. Therefore, XRD analysis confirmed DSC
results for the synthesized derivative inclusion complex could be
attributed to the partial complexation of the drug in the CD cavity
[37].
ESI-MS Analysis. Relative abundances and stoichiometries
of the inclusion complex ABZ:C-b-CD formed by SD was
determined using ESI-MS. The analysis in positive ionization
mode allowed us to observe a molecular ion with m/z 1574.4650.
This revealed that the inclusion complex was formatted in a ratio
1:1 drug:carrier; which is in agreement with the results obtained
from the solubility diagrams. No signals were observed with a ratio
m/z related to other complex stoichiometries. Thereafter, the
molecular ion was analyzed by MS-MS. The fragmentation of 1:1
ABZ:C-b-CD is shown in Figure 6. The major molecular ions
observed were: ABZ:C-b-CD (1574.4650); C-b-CD (1331.3643); b-
CD (1157.3503) and ABZ (266.0911).
NMR Spectroscopy. After a complete NMR study conduct-
ed to determine the b-CD position modification, it was confirmed
that the hydroxyl groups at the C6 and C2 position have been
substituted by the CA.
Two dimensional NMR spectroscopy provides information
through the observation of intermolecular dipolar cross-correla-
tions. Closely located protons can produce a nuclear Overhauser
effect (NOE) cross-correlation in NOE spectroscopy (NOESY) or
ROESY. Spatial contacts within 0.4 nm from two species are
indicated by the presence of NOE cross-peaks [38].
The protons labels of ABZ and C-b-CD and the ROESY
spectrum obtained from the system ABZ:C-b-CD is shown in
Figure 7. It was feasible to determine that the internal protons (H3,
H5, H6) of C-b-CD were closer to protons of the tail of ABZ (a:
d= 0.80 ppm, b: d= 1.40 ppm and c: d= 2.79 ppm, Figure 7 C).
Additionally, the internal protons of the derivative C-b-CD
presented cross-peak with the aromatic protons of ABZ (e:
d= 7.24 ppm, f: d= 7.37 ppm and g: d= 7.74 ppm). Finally the
cross-peak between aromatic and tail protons of ABZ was
observed in Figure 7 D.
Figure 8. Dissolution profiles. Release profiles of ABZ (raw material), ABZ loaded in PMs, ABZ in the inclusion complexes (b-CD and C-b-CD). ABZ
loaded in PMs (b-CD and CA). Test conditions: 0.1 N HCl, 37uC (n = 3, 6SD).
doi:10.1371/journal.pone.0088234.g008
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Analyzing the results of ROESY spectrum, it could be
concluded that both the aromatic ring and the tail of ABZ are
inside the CD derivative and that the tail is probably folded over
the aromatic ring.
Dissolution Studies. Dissolution profiles were performed to
determine the dissolution rate of ABZ loaded in the systems
ABZ:C-b-CD, ABZ:b-CD (obtained by SD or PM) and ABZ
without any treatment (Figure 8). The profiles corresponding to
ABZ:b-CD and the pure drug showed similar results, reaching
nearly a 20% of drug release after six hours of the running assay.
The ABZ:b-CD (SD) complex and the PM prepared with C-b-
CD and the drug achieved almost 80% of drug release after 6
hours.
The results obtained by the dissolution profiles of ABZ loaded in
the inclusion complex with the C-b-CD prepared by spray drying
exhibited the 100% drug release after 20 minutes of the running
assay. These results remarkably demonstrate the improvement of
the dissolution rate of ABZ, loaded in this synthesized derivative
C- b-CD.
Furthermore, to evaluate the influence of CA in the drug release
rate, it has been performed a PM (CA, ABZ and b-CD) dissolution
profile. The CA amount was calculated based on the meq. of
carboxyl groups in the C-b-CD. Figure 8 showed clearly that the
CA did not affect the ABZ dissolution rate enhancement
confirming the high potency of the C-b-CD as an excipient to
improve remarkably the ABZ solubility and dissolution rate.
Conclusions
In the present study, a b-CD derivative was synthesized. The
reaction was followed efficiently by ESI-MS and the acid-base
titration of the product. The derivative exhibited a high affinity for
ABZ with a Kf 15.3 times higher than the traditional b-CD. The
solubility diagrams presented type AL curves indicating a 1:1 ratio
ABZ:C-b-CD complex. The ABZ loaded in the systems obtained
by SD reflected a significant decrease in its crystallinity, which
suggests a partial inclusion in the carrier. ESI-MS/MS-MS
spectrum confirmed the stoichiometry of the complex and the
ROESY assays showed that the tail and the aromatic ring of ABZ
were inside the cavity of C-b-CD. The drug dissolution rate
displayed exceptional results, achieving 100% drug release after 20
minutes.
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